Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPRG.L Regulatory News (PRG)

  • There is currently no data for PRG

Appointments

5 Dec 2006 07:03

Premier Research Group05 December 2006 For Immediate Release 5 December 2006 PREMIER RESEARCH GROUP plc Premier Research appoints Peter Malamis as the President & General Manager of US Operations Premier Research Group plc (AIM: PRG) ("Premier Research", "Company" or"Group"), the international pharmaceutical services group today announces theappointment of Peter Malamis as the President & General Manager - US Operations. Mr. Malamis' responsibility with Premier Research will be the continued growthand development of the US business. Mr. Malamis was previously with SCIREXCorporation in the position of Senior Vice President & General Manager,Commercial Operations. The Company acquired SCIREX as a wholly-owned subsidiaryin July of this year. His more than 20 years of experience in the pharmaceuticalservices industry spans all phases of product development and commercialization.He joined SCIREX from Galt Associates where he was Vice President of Sales.Prior to Galt, Mr. Malamis held executive positions with MEDTAP International,PAREXEL International, State & Federal Associates and SYNTHESIS. Mr. Malamisobtained his B.A. in Political Science at the University of Richmond and hisM.B.A. in Marketing from George Washington University. He also currently servesas a Board member and advisor to several early-stage pharmaceutical servicescompanies. Dr. John Gilly, Chief Operating Officer of Premier Research Group plc,commented: "We are extremely pleased to have Peter join us in this criticallyimportant role. The Company has increased in depth and therapeutic focus overthe past three years and we expect Peter's experience to contribute greatly tofurther commercial success." Said Mr., Malamis, "I'm looking forward to building the US CRO operation;respected for its expertise, commitment to the customer, quality, andreliability. Our clients are engaged in research critically important tomillions of people. They deserve the best service possible and we intend to giveit to them through our talented, dedicated employees." Enquiries:Premier Research Group plc Dr Simon Yaxley, Chief Executive Officer Tel: 01344 752375 Bernard Gallagher, Chief Financial Officer Tel: 01344 458309www.premier-research.com Buchanan Communications Tel: 020 7466 5000 Lisa Baderoon Rebecca Skye Dietrich About Premier Research Premier Research is dedicated to being a leading solutions-driven CRO leveragingour commitment to therapeutic focus and scientific expertise to deliver servicesof the highest quality for Phase I-IV clinical trials. Premier Research is aleader in clinical research for Analgesia, CNS, Infectious Disease and Oncologyand has a wealth of experience in pediatric research. Premier Research has 28 offices and operates in more than 30 countries acrossEurope and North America. Premier Research employs more than 750 clinicalprofessionals dedicated first and foremost to fulfilling each client'srequirements in a timely, accurate and cost-effective manner. This includes astrong international network of monitors and project management professionalscombined with regulatory, data management, statistical, scientific and medicalexperts, and staff at our well-established network of dedicated clinical sites. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th Dec 20157:00 amPRNCorporate Update
14th Dec 20155:00 pmPRNUpdate on Mothae
24th Nov 20158:50 amRNSResignation of Nominated Adviser and Broker
20th Nov 20151:22 pmRNSUpdate Regarding Suspension
16th Nov 20157:47 amRNSTemporary Suspension
16th Nov 20157:45 amRNSSuspension - Paragon Diamonds Limited
7th Oct 20157:00 amPRNCorporate and Mothae acquisition update
2nd Oct 20155:10 pmPRNHoldings in Company
2nd Oct 20157:00 amPRN$15 million Debt and Revenue Sharing Facility
30th Sep 20157:00 amPRNInterim Results
15th Sep 201511:30 amPRNPositive Technical Study for Mothae Kimberlite Project
7th Aug 20157:00 amPRNGovernment approval for acquisition of Mothae
4th Aug 201512:40 pmPRNResult of AGM
15th Jul 20157:02 amPRNHolding(s) in Company
15th Jul 20157:00 amPRNHolding(s) in Company
14th Jul 20157:00 amPRNMothae Acquisition Update
7th Jul 201511:56 amPRNHolding(s) in Company
29th Jun 20151:34 pmPRNAnnual Report and Notice of AGM
26th Jun 20157:00 amPRNFinal Results
18th Jun 20157:00 amPRNGBP500,000 debt financing & Share buyback programme
5th May 20157:00 amPRNMOU to acquire Mothae Kimberlite Project in Lesotho
25th Mar 20151:50 pmPRNHolding(s) in Company
25th Mar 20151:45 pmPRNHolding(s) in Company
13th Mar 20157:00 amPRNUpdate on Lemphane Diamond Project and Placing
3rd Mar 20157:01 amPRNHolding(s) in Company
3rd Mar 20157:00 amPRNHolding(s) in Company
28th Jan 20157:00 amPRNBinding MoU - US$12m equity and debt finance package
9th Jan 201512:52 pmPRNHolding(s) in Company
12th Dec 20147:01 amPRNShare Buy Back and Total Voting Rights
12th Dec 20147:00 amPRNHolding(s) in Company
9th Dec 201411:43 amPRNResult of General Meeting
8th Dec 20147:00 amPRNHoldings in Company
5th Dec 20147:00 amPRNIssue of Equity
4th Dec 201412:56 pmPRNOperations Update
25th Nov 20147:00 amPRNUpdate on Processing Plant - Lemphane Kimberlite Lesotho
20th Nov 201411:30 amPRNExercise of option by Titanium
17th Nov 20147:00 amPRNSale of large high value diamonds - Lemphane Lesotho
14th Nov 20147:00 amPRNPosting of Circular and Notice of General Meeting
13th Nov 20147:00 amPRNLesotho Subsidiary Board Changes
11th Nov 20147:00 amPRNDirectorate Change
11th Nov 20147:00 amPRNAppointment of Adviser
11th Nov 20147:00 amPRNAcquisition of Lanstead Holding in Company
1st Oct 201410:52 amPRNTotal Voting Rights
26th Sep 20147:00 amPRNIssue of Equity
25th Sep 201410:53 amPRNHoldings in Company
15th Sep 20147:01 amPRNInterim Results
15th Sep 20147:00 amPRNAppointment of Broker
27th Aug 20147:00 amRNSUpdate re: Paragon Diamonds Ltd
27th Aug 20147:00 amPRNBoard Changes & Transfer of Convertible Loan Agreement
15th Jul 20144:21 pmPRNResponse to Press Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.